Guohe Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Guohe Song has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
- Jia Fan
Fudan University
47 shared publications - Qiang Gao
Zhongshan Hospital 20 Shanghai
47 shared publications - Jian Zhou
Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai 200032, China
46 shared publications - Jian Lin
Fudan University 2 Shanghai
43 shared publications - Liangqing Dong
Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, China
43 shared publications - Mao Zhang
Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, China
42 shared publications
Latest Publications
- Open Access
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from An Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS-Mutant Intrahepatic Cholangiocarcinoma
Supplementary Table S7. Patient information.
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from An Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS-Mutant Intrahepatic Cholangiocarcinoma
Supplementary Table S7. Patient information.
- Open Access
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from An Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS-Mutant Intrahepatic Cholangiocarcinoma
Supplementary Table S2. Differential ASEs, primers and sequences information.
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from An Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS-Mutant Intrahepatic Cholangiocarcinoma
Supplementary Table S2. Differential ASEs, primers and sequences information.
- Open Access
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from An Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS-Mutant Intrahepatic Cholangiocarcinoma
Supplementary Table S1. Samples and transcriptomics information.
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from An Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS-Mutant Intrahepatic Cholangiocarcinoma
Supplementary Table S1. Samples and transcriptomics information.
- Open Access
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from An Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS-Mutant Intrahepatic Cholangiocarcinoma
Supplementary Table S6. GO term and KEGG pathway information in Gzmb+ Cd8+ T cells.
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from An Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS-Mutant Intrahepatic Cholangiocarcinoma
Supplementary Table S6. GO term and KEGG pathway information in Gzmb+ Cd8+ T cells.
- Open Access
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from An Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS-Mutant Intrahepatic Cholangiocarcinoma
Supplementary Table S5. Top 200 genes for each T cell cluster obtained by wilcox test with the rank_genes_groups function in Scanpy.
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from An Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS-Mutant Intrahepatic Cholangiocarcinoma
Supplementary Table S5. Top 200 genes for each T cell cluster obtained by wilcox test with the rank_genes_groups function in Scanpy.
- Open Access
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from An Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS-Mutant Intrahepatic Cholangiocarcinoma
Supplementary Table S3. Signature and marker information.
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from An Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS-Mutant Intrahepatic Cholangiocarcinoma
Supplementary Table S3. Signature and marker information.
- Open Access
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from An Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS-Mutant Intrahepatic Cholangiocarcinoma
Supplementary Table S4. Neutrophil-related information.
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from An Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS-Mutant Intrahepatic Cholangiocarcinoma
Supplementary Table S4. Neutrophil-related information.
- Open Access
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-9 from An Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS-Mutant Intrahepatic Cholangiocarcinoma
Supplementary Figure S1. Determination of AS index in iCCA. Supplementary Figure S2. Validation of distinct immune features in iCCA. Supplementary Figure S3. Detection of KRAS mutation associated indicators. Supplementary Figure S4. Exploration of the molecular mechanisms of IL1RN201/203 in iCCA. Supplementary Figure S5. Comparison between KRAS mutant (YAK) or KRASWT (YA) iCCA mice and functional validation of IL1RN-201/203. Supplementary Figure S6. Definition, validation and functional exploration of neutrophil clusters. Supplementary Figure S7. Effects of T cells, especially GZMB+ CD8+ T cells, on IL1RN-201/203 efficacy. Supplementary Figure S8. The roles of anti-PD1 Ab in KRASWT iCCA mice and anti-PD1 Ab plus anakinra in KRAS mutant iCCA mice. Supplementary Figure S9. Immunologic features of cancer patients with or without KRAS mutation.
- 12 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-9 from An Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS-Mutant Intrahepatic Cholangiocarcinoma
Supplementary Figure S1. Determination of AS index in iCCA. Supplementary Figure S2. Validation of distinct immune features in iCCA. Supplementary Figure S3. Detection of KRAS mutation associated indicators. Supplementary Figure S4. Exploration of the molecular mechanisms of IL1RN201/203 in iCCA. Supplementary Figure S5. Comparison between KRAS mutant (YAK) or KRASWT (YA) iCCA mice and functional validation of IL1RN-201/203. Supplementary Figure S6. Definition, validation and functional exploration of neutrophil clusters. Supplementary Figure S7. Effects of T cells, especially GZMB+ CD8+ T cells, on IL1RN-201/203 efficacy. Supplementary Figure S8. The roles of anti-PD1 Ab in KRASWT iCCA mice and anti-PD1 Ab plus anakinra in KRAS mutant iCCA mice. Supplementary Figure S9. Immunologic features of cancer patients with or without KRAS mutation.
- Top Cited PapersOpen Access
- 28 January 2025
- Published by Springer Nature in Cell Discovery
- Vol. 11 (1) , 1-24
Stromal architecture and fibroblast subpopulations with opposing effects on outcomes in hepatocellular carcinoma
Dissecting the spatial heterogeneity of cancer-associated fibroblasts (CAFs) is vital for understanding tumor biology and therapeutic design. By combining pathological image analysis with spatial proteomics, we revealed two stromal archetypes in hepatocellular carcinoma (HCC) with different biological functions and extracellular matrix compositions. Using paired single-cell RNA and epigenomic sequencing with Stereo-seq, we revealed two fibroblast subsets CAF-FAP and CAF-C7, whose spatial enrichment strongly correlated with the two stromal archetypes and opposing patient prognosis. We discovered two functional units, one is the intratumor inflammatory hub featured by CAF-FAP plus CD8_PDCD1 proximity and the other is the marginal wound-healing hub with CAF-C7 plus Macrophage_SPP1 co-localization. Inhibiting CAF-FAP combined with anti-PD-1 in orthotopic HCC models led to improved tumor regression than either monotherapy. Collectively, our findings suggest stroma-targeted strategies for HCC based on defined stromal archetypes, raising the concept that CAFs change their transcriptional program and intercellular crosstalk according to the spatial context.
- 28 January 2025
- Published by Springer Nature in Cell Discovery
- Vol. 11 (1) , 1-24
Top Cited PapersOpen AccessStromal architecture and fibroblast subpopulations with opposing effects on outcomes in hepatocellular carcinoma
Dissecting the spatial heterogeneity of cancer-associated fibroblasts (CAFs) is vital for understanding tumor biology and therapeutic design. By combining pathological image analysis with spatial proteomics, we revealed two stromal archetypes in hepatocellular carcinoma (HCC) with different biological functions and extracellular matrix compositions. Using paired single-cell RNA and epigenomic sequencing with Stereo-seq, we revealed two fibroblast subsets CAF-FAP and CAF-C7, whose spatial enrichment strongly correlated with the two stromal archetypes and opposing patient prognosis. We discovered two functional units, one is the intratumor inflammatory hub featured by CAF-FAP plus CD8_PDCD1 proximity and the other is the marginal wound-healing hub with CAF-C7 plus Macrophage_SPP1 co-localization. Inhibiting CAF-FAP combined with anti-PD-1 in orthotopic HCC models led to improved tumor regression than either monotherapy. Collectively, our findings suggest stroma-targeted strategies for HCC based on defined stromal archetypes, raising the concept that CAFs change their transcriptional program and intercellular crosstalk according to the spatial context.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from An inflammatory checkpoint generated by IL1RN splicing offers therapeutic opportunity for KRAS mutant intrahepatic cholangiocarcinoma
Supplementary Table S2. Differential ASEs, primers and sequences information.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from An inflammatory checkpoint generated by IL1RN splicing offers therapeutic opportunity for KRAS mutant intrahepatic cholangiocarcinoma
Supplementary Table S2. Differential ASEs, primers and sequences information.